卡思克鲁力重申同Medebound美联医邦的独家合作关系

2018-05-31

正文




美通社1月23日电,美国医疗评鉴机构卡思克鲁力(Castle Connolly Medical Ltd)重申同Medebound美联医邦的独家战略合作,终止与More Health的短暂合作关系。


以下为新闻中文翻译:


Castle Connolly Medical Ltd. 卡思克鲁力是位于纽约的一家医疗健康领域研究和信息的机构,以其品牌America's Top Doctors(美国顶级医生)而闻名,该公司宣布终止与More Health短暂的合作关系。


Castle Connolly卡思克鲁力将会继续与其在中国的独家合作伙伴Medebound LLC(中文名:美联医邦)合作,为中国患者和医生提供服务。美联医邦公司总裁兼首席执行官Sheena Liu博士表示,能与Castle Connolly合作感到非常荣幸。“ 我们和Castle Connolly卡思克鲁力在过去的几年中保持着非常友好和高效的合作,共同致力于服务中国市场,通过保险公司、雇主为患者提供美国顶级专家的第二诊疗意见服务,业务已经逐渐发展壮大。”


美联医邦已与中国最大的保险公司的其中三家在总部层面已经签署了重要合同(这些保险公司的规模与美国保险巨头譬如Metlife或UnitedHealth相似),100%覆盖美联医邦的远程第二意见的费用和其他辅助服务,保障和惠及了数十万名中国高端客户。


Castle Connolly卡思克鲁力总裁兼首席执行官John Connolly博士表示:“我们很高兴能继续深化与Medebound美联医邦的合作关系,并协助中国患者获得美国最顶尖医生的医疗意见。”


关于美联医邦

美联医邦®(www.medebound.com)成立于2015年,总部在纽约,是一家致力于连接中国患者和医生与美国医生的远程医疗及第二诊疗意见机构。公司开发的专利远程医疗平台既提供双语服务,又兼容美国HIPAA(健康保险交换与责任法案)隐私条例,确保了中国患者/医生和美国顶级医生之间进行影像、病历翻译,传输和远程咨询的安全性和高效性。通过与Castle Connolly Top Doctors卡思克鲁力顶级医生的独家战略合作/股权投资关系,建立了权威可信,横跨72个专科的52,000多名美国医生的美国顶级医生资源。凭借高度差异化的医生资源,先进的双语IT平台以及在美国和中国的强有力运营团队,美联医邦在中国已经获得了可观的市场吸引力。


关于Castle Connolly Medical Ltd.

Castle Connolly Medical Ltd.(www.castleconnolly.com)卡思克鲁力是一家医疗服务调研 、并出版发行顶级医生名录的机构。成立近三十年以来,始终致力于帮助消费者在全美及各地区寻找优质可靠的医疗服务和顶级医生资源。 Castle Connolly Top Doctors拥有横跨72个专科、超过52,000名美国医生的在线数据库,这些顶级医生名录是由同行提名,并经过了由医生领导的研究团队严格筛选产生的。这个顶级医生名录可以帮助患者通过医生名字、地点、专科、医院和疾病/病情进行搜索,寻找到最好的并适合患者病情的当地或者全国最顶级的医生。 Castle Connolly是美国50多个地区杂志,同时也是很多主要的国家级杂志和报纸以及各种网络媒体平台的的顶级医生信息来源。 2017年,该网站的访问量超过1.1亿。


刘欣娜博士与克鲁力博士(左)和卡思先生(后)在纽约办公室举行的签约仪式,共同组建美联医邦董事会


新闻原文


Castle Connolly Medical Ltd., a New York based healthcare research and information company noted for its brand America’s Top Doctors®, and More Health, Inc. a California based medical second opinion company with operations in China, have ended a brief relationship. Castle Connolly will continue to work with its exclusive partner in China, Medebound LLC, in serving Chinese patients, doctors and hospitals. Sheena Liu, M.D., Ph.D., the President and CEO of Medebound, stated that she was pleased with her company’s relationship with Castle Connolly. “We have enjoyed a very positive and productive relationship with Castle Connolly through past years. Our second medical opinion business serving insurers, employers and patients has grown substantially and together we are committed to the Chinese market.” Medebound has executed important contracts with 3 of the largest insurance companies in China with size similar to Metlife or UnitedHealth in the US, at the headquarter level reaching hundreds of thousand Chinese clients whose insurance health benefits 100% cover/reimburse Medebound’s remote second opinions and other ancillary services. “We are delighted to continue to expand our relationship with Medebound and to help assist Chinese healthcare consumers seeking the expertise of the most America’s Top Doctors”,“ said Dr. John Connolly, Castle Connolly’s President and CEO


About Medebound LLC

Founded in 2015, Medebound (www.medebound.com) is a tele-health/second opinion company headquartered in New York with the focus on connecting Chinese patients/physicians with US doctors. This is achieved by creating a proprietary bi-lingual HIPAA-compliant tele-health platform, which facilitates secure medical imaging/records translation, transferring and tele-consultations between Chinese patients/local physicians and leading American specialists; and by establishing an exclusive strategic/equity relationship with Castle Connolly Top Doctors®, an established, trusted and authoritative resource for identifying America’s leading physicians, with more than 52,000 U.S. physicians across 72 medical specialties. With this highly-differentiated physician resource and first-of-its-kind bilingual IT platform and a strong execution team operating both in the US and China, Medebound has gained significant market traction.


About Castle Connolly Medical Ltd.

Castle Connolly Medical Ltd. (www.castleconnolly.com) is a healthcare research, information, and publishing company whose mission since its inception nearly three decades ago is to help consumers find independent, trusted information about quality healthcare and Top Doctors on both the regional and national levels. Castle Connolly Top Doctors®, an online database of more than 52,000 U.S. physicians across 72 medical specialties who have been nominated by their peers and rigorously screened by its physician-led research team, is used widely by focused healthcare consumers who seek the best healthcare. This database is searchable by physician name, location, specialty, hospital, and disease/condition. Castle Connolly is the source of Top Doctors’ information for more than 50 regional magazines across the U.S., many major national magazines and newspapers, and diverse online media distribution platforms. In 2017, visitors to the website generated 110 Million+ views of Castle Connolly Top Doctors detailed profiles.


相关链接:

1. https://www.prnewswire.com/news-releases/castle-connolly-medical-ltd-and-more-health-inc-mutually-terminate-their-relationship-300586299.html

2. http://markets.businessinsider.com/news/stocks/Castle-Connolly-Medical-Ltd-and-More-Health-Inc- utually-Terminate-Their-Relationship-1001689333

3. http://www.castleconnolly.com/

4. http://www.medebound.com/


本文由美联医邦Medebound原创,欢迎转发,未经美联医邦允许,不得转载,违者必究。

部分美联医邦美国名医真实案例

中国还原体肌病患儿获美国专家免费5+小时多学科会诊、免费食宿,感恩遇见美国最高政府卫生研究院

膀胱癌患者通过视频会诊中美两国三地联线哈佛名医,寻求治疗方案及临床试验建议

☞波士顿儿童医院专家治疗五岁脑积水患儿

☞美国约翰霍普金斯医院专家视频为白血病患者提出治愈性方案 

 微信公众号:medebound


   


   

   

   

Eric P. Winer 医学博士
Eric P. Winer 医学博士

美国哈佛大学丹娜法伯癌症研究所乳腺癌中心主任

妇女癌症司科长

擅长专科:乳腺癌

就职医院:美国哈佛大学丹娜法伯癌症研究所

 

丹娜法伯癌症研究院成立于1947年,是美国哈佛大学医学院的癌症专科附属医院,美国联邦政府指定的综合性癌症治疗中心,产生了1位诺贝尔医学奖获得者。在癌症基因定位治疗、癌症免疫治疗、癌症内分泌治疗、癌症生物治疗、癌症疫苗等临床方面世界领先。成人肿瘤的治疗优势全美领先;儿童肿瘤的治疗更是历年全美排名第一。

 

教育背景:

医学院培训:耶鲁大学医学院

住院医师培训:耶鲁大学医学院

专科医师培训:杜克大学医学中心血液肿瘤科

 

获奖:

2017年,美国临床肿瘤学会Gianni bonadonna乳腺癌奖;

2016年,圣安东尼奥乳腺癌研讨会上获得William L. McGuire纪念奖;

2009年,哈佛大学医学院A. Clifford Barger优秀导师奖;

2006年,丹娜法伯癌症研究所杰出成就奖;

2002年,Claire W. and Richard P. Morse研究奖;

1999年,杜克大学约瑟夫索卡尔纪念讲师奖章。

卡思克鲁力评选的美国最佳医生(America’s  Top Doctors)

Ibrance(palbociclib)
Ibrance(palbociclib)

生产厂商:辉瑞(Pfizer)

美国批准日期: 2015年2月3日

适应症:雌激素受体阳性(ER+)、人表皮生长因子受体2阴性(HER2-)的妇女晚期乳腺癌

剂型/给药途径:口服

中国是否获批:2018年7月31日获批

2015年02月03日,美国FDA批准辉瑞公司的Ibrance胶囊上市,与来曲唑联合用于,是首个获批的细胞周期蛋白依赖激酶4和6(CDK4/6)抑制剂,Ibrance的成功上市对CDKs抑制剂的研发具有里程碑意义。

Ibrance有125mg、100mg、75mg三种规格。Ibrance与食物同服,并与来曲唑联合用药,推荐的起始剂量为125mg,每日1次,连续服用21d,之后停药7d,一个疗程为28d;推荐根据个体安全性及耐受性中断治疗和/或减少剂量。

联系我们

纽约
260 Madison Ave 8th Floor #8001, New York, NY 10016
(美)+1 17182138508
(中) +86 400-616-2591
support@medebound.com

Medebound 微信公众号

400-616-2591
© Copyright Medebound 2021. All Rights Reserved.
蜀ICP备15017512号
热线:400-616-2591
微信